Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
None (31) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fetzima (1) ·
ketalar (1) ·
Laudanum, Dropizol (1) ·
Lithobid (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Nuedexta (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Ultracet, Tramacet (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
5HT1a (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
NMDA-receptor antagonism (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Source of DMT-class tryptamines (1) ·
Source of [[DMT]], bufotenine, and 5-MeO-DMT (1) ·
Source of [[DMT|N,N-dimethyltryptamine]] (1) ·
TBD (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-00001580-QINU`"' First FDA-approved treatment for PBA. The 10 mg quinidine daily dose is far below antiarrhythmic levels but sufficient to nearly fully inhibit CYP2D6, the basis of the combination's pharmacokinetic rationale'"`UNIQ--ref-00001581-QINU`"'. (1) ·
µ-opioid agonism (1)
uses:
starting dose:
preparations:
fda max:
onset:
duration:
halflife:
None (50) ·
Dextromethorphan substantially prolonged by quinidine's CYP2D6 inhibition (typical extensive metabolizers see ~10× higher AUC); quinidine ~6-8 hours'"`UNIQ--ref-00001583-QINU`"' (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
pregnancy:
None (50) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data; quinidine has been used in pregnancy as antiarrhythmic.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (50) ·
Rx-only (1) ·
Rx-only in US (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Caution with QT-prolonging medicines (quinidine itself is class IA antiarrhythmic, and the dose here, though sub-antiarrhythmic, still contributes to QT)'"`UNIQ--ref-00001585-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 54 results in range #1 to #54.